Zacks Investment Research
15 Jul 2026, 14:55 UTC · 12w ago
Verdict
Headline takes no side. We score HRMY +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Analysts have reached a consensus that Harmony Biosciences (HRMY) will report earnings that exceed previous estimates.
More positive than 79% of claims this week
The mean analyst price target for HRMY is $44.33, representing a potential upside of 27.4% from its last close of $34.81.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company has a positive consensus price target with upside potential and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
+9.8%
Price agrees with the score
$38.23 vs $34.81 close before publication (Jul 14) · not market-adjusted
HRMY chart →
